NCT03946527 2026-03-02
LAMPARA
Columbia University
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT06607692 2024-10-21
LUPARPED
Fundación de investigación HM
Phase 2 Recruiting
NCT06045260 2024-08-13
LUFOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT05885386 2023-06-01
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05883085 2023-05-31
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04276597 2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Withdrawn
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT05133349 2021-11-24
EASOAIPPGL
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT04106843 2020-09-07
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04029428 2020-04-01
POLNETS_PRRT
University of Warmia and Mazury
Phase 2 Unknown
NCT01413503 2018-09-18
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Phase 2 Completed